THERION/NCI CANCER IMMUNOTHERAPEUTICS CRADA
Executive Summary
THERION/NCI CANCER IMMUNOTHERAPEUTICS CRADA calls for Therion to "generate vaccine candidates based on live recombinant poxvirus vectors that express specific tumor-associated antigens" characterized by the National Cancer Institute, the privately held Cambridge, Mass.-based company announced Nov. 1. NCI Surgery Branch Chief Steven Rosenberg, MD/PhD, will be the agency's principal investigator for the five-year collaboration.
You may also be interested in...
Bavarian Nordic To Take Prostvac Therapeutic Prostate Cancer Vaccine Into Phase III
Danish firm won license for the therapy, once held by defunct Therion, in CRADA with NCI.
Bavarian Nordic To Take Prostvac Prostate Cancer Vaccine Into Phase III
Bavarian Nordic's attempt to reduce the risk associated with developing a cancer vaccine includes licensing a vetted therapy from the National Cancer Institute and developing it with the institute under a Cooperative Research and Development Agreement.
Bavarian Nordic To Take Prostvac Prostate Cancer Vaccine Into Phase III
Bavarian Nordic's attempt to reduce the risk associated with developing a cancer vaccine includes licensing a vetted therapy from the National Cancer Institute and developing it with the institute under a Cooperative Research and Development Agreement.